p hh3 (Cell Signaling Technology Inc)
Structured Review

P Hh3, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 98/100, based on 1314 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/p hh3/product/Cell Signaling Technology Inc
Average 98 stars, based on 1314 article reviews
Images
1) Product Images from "CircSARS-CV2-N1368 from SARS-CoV-2 impairs endothelial cell function through the upregulation of ATF7 to activate TLR4/NF-κB/ROS signaling."
Article Title: CircSARS-CV2-N1368 from SARS-CoV-2 impairs endothelial cell function through the upregulation of ATF7 to activate TLR4/NF-κB/ROS signaling.
Journal: Acta pharmacologica Sinica
doi: 10.1038/s41401-025-01516-8
Figure Legend Snippet: Fig. 5 CircSARS-CV2-N1368 inhibits proliferation, migration and tube-formation of HCMECs via sponging miR-103a-3p. a Effect of miR- 103a-3p on expression of VEGFA, e-NOS and HH3 activation in circSARS-CV2-N1368-overexpressiong HCMECs by Western blot assay. b MiR- 103a-3p decreased ROS level in circSARS-CV2-N1368 overexpressing HCMECs. c Proliferation activity analysis of HCMECs by EdU assay. d, e Migration activity analysis of HCMECs by trans-well migration assay and wound healing assay, respectively. f Matrigel tube formation assay of circSARS-CV2-Ns-overexpressiong HCMECs with transfection of miR-103a-3p. Comparisons were made with 1-way ANOVA, n = 3 per group in (b)–(f). The scale bar is 50 μm in (b), (c), (e), the scale bar is 100 μm in (f), the scale bar is 200 μm in (d). *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Migration, Expressing, Activation Assay, Western Blot, Activity Assay, EdU Assay, Wound Healing Assay, Tube Formation Assay, Transfection
Figure Legend Snippet: Fig. 6 CircSARS-CV2-N1368 regulates the phenotypes of HCMECs by targeting miR-103a-3p/Atf7 axis. a Venn diagram showing the overlapped genes. b and c The expression of the concerned genes in HCMECs with transfection of miR-103a-3p by RT-qPCR assay. d Validation of the interaction between miR-103a-3p and Atf7 mRNA by RIP assay. e Determination of ATF7 and VEGFA expression, activations of e-NOS, HH3 and NF-κB p65 in HCMECs by Western blot assay. f MiR-103a-3p and si-Atf7 decreased ROS generation in circSARS-CV2-N1368 overexpressing HCMECs. g Proliferation activity analysis of HCMECs by EdU assay. h, i Migration activity of HCMECs by trans-well migration assay and wound healing assay, respectively. j Matrigel tube formation assay of circSARS-CV2-Ns-overexpressiong HCMECs with transfection of miR-103a-3p or si-Atf7. Comparisons were made with unpaired t test in (b)–(d), and comparisons were made with 1-way ANOVA in (e)–(i), n = 3 per group. The scale bar is 50 μm in (f)–(h), the scale bar is 100 μm in i, the scale bar is 200 μm in (j). **P < 0.01, ***P < 0.001.
Techniques Used: Expressing, Transfection, Quantitative RT-PCR, Biomarker Discovery, Western Blot, Activity Assay, EdU Assay, Migration, Wound Healing Assay, Tube Formation Assay
Figure Legend Snippet: Fig. 8 NAC treatment reverses the effect of circSARS-CV2-N1368 on impairment of HCMECs. a Detection of ROS level in circSARS-CV2- N1368 overexpressing HCMECs by using DCFH-DA probe. b Western blotting analysis of VEGFA expression, activations of e-NOS and HH3 in NAC-treated HCMECs with overexpression of circSARS-CV2-N1368. c Proliferation activity analysis of HCMECs by EdU assay. d, e Migration activity analysis of HCMECs was evaluated by trans-well migration assay and wound healing assay, respectively. f NAC rescued matrigel tube formation of HCMECs with overexpression of circSARS-CV2-N1368. Comparisons were made with 1-way ANOVA, n = 3 per group in (a)–(f), and 2-way ANOVA, n = 3 per group in (b), The scale bar is 50 μm in (a), (c), (d), the scale bar is 100 μm in (f), the scale bar is 200 μm in (e). *P < 0.05, **P < 0.01, ***P < 0.001.
Techniques Used: Western Blot, Expressing, Over Expression, Activity Assay, EdU Assay, Migration, Wound Healing Assay

